Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.65 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.65 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.60 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.60 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7494872 | 0.98 | SMN1; SMN2 (0.74) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL23989211 | 0.98 | SMN1; SMN2 (0.74) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL11928063 | 0.94 | SMN1; SMN2 (0.81) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| Carbamic Acid SCHEMBL4671849 | 0.93 | SMN1; SMN2 (0.67) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| Hexadecanoic Acid Cyclopentylamide SCHEMBL1456473 | 0.92 | SMN1; SMN2 (0.78) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL1456736 | 0.92 | SMN1; SMN2 (0.78) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL22055472 | 0.92 | SMN1; SMN2 (0.78) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL11525129 | 0.92 | SMN1; SMN2 (0.78) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL931252 | 0.92 | SMN1; SMN2 (0.78) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL28342770 | 0.92 | SMN1; SMN2 (0.78) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271246-A | Method for continuously preparing 2-butyl-1, 3-diazaspiro [4.4] nonane-1-en-4-one | 浙江华海药业股份有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-101239975-A | Synthesis of 2-butyl-3-(2'-(1-trityl-1h-tetrazol-5-yl)biphenyl-4-yl)methyl-1,3-diazaspirol[4,4]-non-ene-4-one | TEVA PHARMA (IL) | 2008-08-13 | — | — | CN | claimed |
| EP-1590343-B1 | SYNTHESIS OF 2-BUTYL-3-(2' -(1-TRITYL-1H-TETRAZOL-5-YL)BIPHEN YL-4-YL)-1,3-DIAZASPIRO-4,4 -NONENE-4-ONE | TEVA PHARMA (IL) | 2008-07-16 | — | — | EP | claimed |
| CN-1771246-A | Synthesis of 2-butyl-3- (2' - (1-trityl-1H-tetrazol-5-yl) biphenyl-4-yl) -1, 3-diazaspiro [4.4] non-en-4-one | TEVA PHARMA (IL) | 2006-05-10 | — | — | CN | claimed |
| EP-1590343-A1 | SYNTHESIS OF 2-BUTYL-3-(2 -(1-TRITYL-1H-TETRAZOL-5-YL)BIPHEN YL-4-YL)-1,3-DIAZASPIROL 4,4 -NON-ENE-4-ONE | Teva Pharmaceutical Industries Limited (IL) | 2005-11-02 | — | — | EP | claimed |
| US-20040242894-A1 | Novel synthesis of 2-butyl-3-(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one | TEVA PHARMACEUTICALS USA, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004072064-A1 | SYNTHESIS OF 2-BUTYL-3-(2'-(1-TRITYL-1H-TETRAZOL-5-YL)BIPHENYL-4-YL)-1,3-DIAZASPIROL[4,4]-NON-ENE-4-ONE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-08-26 | — | — | WO | claimed |
| EP-0998463-A1 | PROCESS FOR THE PREPARATION OF 1,3-DIAZA-SPIRO (4.4) NON-1-EN-4-ONE DERIVATIVES AND 1-CYANO-1-ACYLAMINOCYCLOPENTANE INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 2000-05-10 | — | — | EP | claimed |
| EP-0998462-A1 | PROCESS FOR THE PREPARATION OF 1,3-DIAZA-SPIRO (4.4) NON-1-EN-4-ONE DERIVATIVES AND 1-CYANO-1-ACYLAMINO-CYCLOPENTANE INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 2000-05-10 | — | — | EP | claimed |
| WO-1999005119-A1 | PROCESS FOR THE PREPARATION OF 1,3-DIAZA-SPIRO (4.4) NON-1-EN-4-ONE DERIVATIVES AND 1-CYANO-1-ACYLAMINO-CYCLOPENTANE INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 1999-02-04 | — | — | WO | claimed |
| WO-1999005120-A1 | PROCESS FOR THE PREPARATION OF 1,3-DIAZA-SPIRO (4.4) NON-1-EN-4-ONE DERIVATIVES AND 1-CYANO-1-ACYLAMINOCYCLOPENTANE INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 1999-02-04 | — | — | WO | claimed |
| CN-118724999-A | Synthesis of cholic acid derivative and application of cholic acid derivative as TGR5 allosteric agonist | 常州大学 | 2024-10-01 | — | — | CN | disclosed |
| CN-115710298-B | Cholic acid derivative, preparation method thereof and application of cholic acid derivative as TGR5 allosteric agonist | 常州大学 | 2024-10-01 | — | — | CN | disclosed |
| CN-118271246-A | Method for continuously preparing 2-butyl-1, 3-diazaspiro [4.4] nonane-1-en-4-one | 浙江华海药业股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| WO-2023168974-A1 | CHOLIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF AS TGR5 ALLOSTERIC AGONIST | 常州大学 | 2023-09-14 | — | — | WO | disclosed |
| WO-2004072064-A1 | SYNTHESIS OF 2-BUTYL-3-(2'-(1-TRITYL-1H-TETRAZOL-5-YL)BIPHENYL-4-YL)-1,3-DIAZASPIROL[4,4]-NON-ENE-4-ONE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-08-26 | — | — | WO | disclosed |
| EP-1089978-A4 | PROCESS FOR PREPARING OXIMIDAZOLES | SALSBURY CHEMICALS INC (US) | 2003-08-06 | — | — | EP | disclosed |
| EP-1089978-A1 | PROCESS FOR PREPARING OXIMIDAZOLES | Salsbury Chemicals, Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000000476-A1 | PROCESS FOR PREPARING OXIMIDAZOLES | SALSBURY CHEMICALS, INC. (US) | 2000-01-06 | — | — | WO | disclosed |
| US-5910595-A | Process for preparing oximidazoles | SALSBURY CHEMICALS, INC. (US) | 1999-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242894-A1 | Novel synthesis of 2-butyl-3-(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one | AGTR1, AGTR2, TEK | SMN1; SMN2 4121/4885HDAC3 330/4885HDAC1 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.